Citigroup
PGNX

Citigroup’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Citigroup’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-200
Closed -$1K – 7815
2020
Q1 		$1K Sell
200
-11,900
-98% -$51.3K ﹤0.01% 7560
2019
Q4 		$62K Hold
12,100
– – ﹤0.01% 6148
2019
Q3 		$61K Sell
12,100
-22,300
-65% -$111K ﹤0.01% 6005
2019
Q2 		$212K Sell
34,400
-34,500
-50% -$166K ﹤0.01% 5215
2019
Q1 		$320K Buy
68,900
+37,100
+117% +$168K ﹤0.01% 4637
2018
Q4 		$134K Sell
31,800
-1,800
-5% -$9.16K ﹤0.01% 5410
2018
Q3 		$211K Sell
33,600
-8,600
-20% -$66.1K ﹤0.01% 5201
2018
Q2 		$339K Sell
42,200
-21,600
-34% -$165K ﹤0.01% 4498
2018
Q1 		$476K Buy
63,800
+17,300
+37% +$115K ﹤0.01% 4042
2017
Q4 		$277K Buy
46,500
+14,900
+47% +$90.5K ﹤0.01% 4736
2017
Q3 		$233K Buy
31,600
+15,300
+94% +$97.2K ﹤0.01% 4862
2017
Q2 		$111K Buy
16,300
+8,200
+101% +$60.5K ﹤0.01% 5273
2017
Q1 		$76K Buy
8,100
+2,200
+37% +$22K ﹤0.01% 5413
2016
Q4 		$51K Buy
+5,900
New +$43.6K ﹤0.01% 6140

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Citigroup's PGNX Position: Q2 2020 in Review

Citigroup sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 79,324 shares — an estimated $301K sold.

Citigroup first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $2.37M in Q4 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Citigroup reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Citigroup sold 79,324 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $301K.
  • Citigroup first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
  • Citigroup's Progenics Pharmaceuticals Inc position peaked at $2.37M in Q4 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Citigroup's 13F filing for Q2 2020, filed 12 Aug 2020.